NCT06233942 2026-03-18
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
12 trialsNCT05981703 2026-03-04
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06422520 2026-02-23
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT04649385 2026-02-20
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT07414836 2026-02-17
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Not yet recruiting
NCT07396090 2026-02-09
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
NCT05547321 2025-11-25
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
Phase 1 Recruiting
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT05508100 2024-05-24
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Immune-Onc Therapeutics
Phase 1 Completed
NCT05840835 2023-08-08
IMMINENT-01
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed